Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.66 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.66 |
| ▸ | PI4KA | P42356 | 2/20 | 0.52 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.52 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.52 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | DRD3 | P35462 | 1/20 | 0.52 |
| ▸ | XDH | P47989 | 1/20 | 0.52 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.52 |
| ▸ | CDK2 | P24941 | 3/20 | 0.47 |
| ▸ | DPP4 | P27487 | 1/20 | 0.47 |
| ▸ | PNP | P00491 | 1/20 | 0.46 |
| ▸ | POLA1 | P09884 | 2/20 | 0.43 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.43 |
| ▸ | BRAF | P15056 | 2/20 | 0.41 |
| ▸ | CDK1 | P06493 | 2/20 | 0.40 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isoguanine SCHEMBL29569323 | 1.00 | PDPK1 (0.66) | PDPK1GDAPI4KAPI4K2BPI4K2A | |
| Isoguanine SCHEMBL28881043 | 0.93 | PDPK1 (0.58) | PDPK1GDAPI4KAPI4K2BPI4K2A | |
| Isoguanine SCHEMBL28597773 | 0.90 | PI4KA (0.71) | PDPK1GDAPI4KAPI4K2BPI4K2A | |
| 2,6-Diaminopurine SCHEMBL6839643 | 0.85 | PDPK1 (0.72) | PDPK1GDAPI4KAPI4K2BPI4K2A | |
| Isoguanine SCHEMBL10380136 | 0.84 | GDA (0.49) | PDPK1GDAPI4KAPI4K2BPI4K2A | |
| SCHEMBL8851 | 0.80 | PDPK1 (0.66) | PDPK1GDAPI4KAPI4K2BPI4K2A | |
| SCHEMBL29375265 | 0.80 | PDPK1 (0.66) | PDPK1GDAPI4KAPI4K2BPI4K2A | |
| SCHEMBL94774 | 0.80 | PDPK1 (0.66) | PDPK1GDAPI4KAPI4K2BPI4K2A | |
| SCHEMBL29421402 | 0.80 | PDPK1 (0.66) | PDPK1GDAPI4KAPI4K2BPI4K2A | |
| Xanthine SCHEMBL4966 | 0.79 | GDA (0.44) | PDPK1GDAPI4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 420 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260098287-A1 | METHOD AND KIT FOR REGENERATING REUSABLE INITIATORS FOR NUCLEIC ACID SYNTHESIS | CHENG-YAO CHEN (TW) | 2026-04-09 | — | — | US | claimed |
| EP-3922266-B1 | TOLL-LIKE RECEPTOR 7 OR 8 AGONIST-CHOLESTEROL COMPLEX, AND USE OF SAME | PROGENEER INC (KR) | 2026-04-08 | — | — | EP | claimed |
| CN-113960312-B | Serum metabolism marker for diagnosing benign and malignant lung nodules and application thereof | 上海市第一人民医院 | 2025-03-04 | — | — | CN | claimed |
| CN-118150834-A | Application of marker in preparation of product for predicting IgG antibody endurance | 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） | 2024-06-07 | — | — | CN | claimed |
| CN-117877567-A | Metabolic marker for clinical early diagnosis of smoke disease and application thereof | 河南省人民医院 | 2024-04-12 | — | — | CN | claimed |
| CN-117321218-A | Regeneration method and kit of reusable initiators for nucleic acid synthesis | 陈呈尧 | 2023-12-29 | — | — | CN | claimed |
| US-20230410977-A1 | METHODS AND MATERIALS FOR ASSESSING RADIATION EXPOSURE | NUTECH VENTURES | 2023-12-21 | — | — | US | claimed |
| US-20230390406-A1 | Star Polymer Drug Conjugates | BARINTHUS BIOTHERAPEUTICS NORTH AMERICA, INC. | 2023-12-07 | — | — | US | claimed |
| US-20230348903-A1 | OLIGONUCLEOTIDES | Hudson Institute of Medical Research (AU) | 2023-11-02 | — | — | US | claimed |
| EP-4263852-A1 | METHOD AND KIT FOR REGENERATING REUSABLE INITIATORS FOR NUCLEIC ACID SYNTHESIS | Chen, Cheng-Yao (TW) | 2023-10-25 | — | — | EP | claimed |
| US-20030096286-A1 | Oligoribonucleotides and ribonucleases for cleaving RNA | ISIS PHARMACEUTICALS, INC. | 2003-05-22 | — | — | US | claimed |
| US-20030003454-A1 | Methods and kits for determining a risk to develop cancer, for evaluating an effectiveness and dosage of cancer therapy and for correlating between an activity of a DNA repair enzyme and a cancer | YEDA RESEARCH AND DEVELOPMENT CO. LTD. AT THE WEIZMANN INSTITUTE OF SCIENCE | 2003-01-02 | — | — | US | claimed |
| US-20020165189-A1 | Oligoribonucleotides and ribonucleases for cleaving RNA | ISIS PHARMACEUTICALS, INC. | 2002-11-07 | — | — | US | claimed |
| WO-2002076280-A2 | METHODS AND KITS FOR DETERMING A RISK TO DEVELOP CANCER, FOR EVALUATING AN EFFECTIVENESS AND DOSAGE OF CANCER THERAPY AND FOR CORRELATING BETWEEN AN ACTIVITY OF A DNA REPAIR ENZYME AND A CANCER | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2002-10-03 | — | — | WO | claimed |
| JP-2000510446-A | — | — | 2000-08-15 | — | — | JP | claimed |
| EP-0928290-A4 | OLIGORIBONUCLEOTIDES AND RIBONUCLEASES FOR CLEAVING RNA | ISIS PHARMACEUTICALS INC (US) | 2000-01-19 | — | — | EP | claimed |
| EP-0928290-A1 | OLIGORIBONUCLEOTIDES AND RIBONUCLEASES FOR CLEAVING RNA | ISIS PHARMACEUTICALS, INC. (US) | 1999-07-14 | — | — | EP | claimed |
| US-5898031-A | Oligoribonucleotides for cleaving RNA | ISIS PHARMACEUTICALS, INC. (US) | 1999-04-27 | — | — | US | claimed |
| WO-1997046570-A1 | OLIGORIBONUCLEOTIDES AND RIBONUCLEASES FOR CLEAVING RNA | ISIS PHARMACEUTICALS, INC. (US) | 1997-12-11 | — | — | WO | claimed |
| US-5352786-A | Di(2-propyl)esters of 1-fluoro-2-phosphonomethoxy-3-P-to-luenesulfonyloxypropanes, their producing and utilization | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CS) | 1994-10-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260098287-A1 | METHOD AND KIT FOR REGENERATING REUSABLE INITIATORS FOR NUCLEIC ACID SYNTHESIS | DNMT3L, ADAR, UNG | PDPK1 3057/4885GDA 113/4885PI4KA 2032/4885 |
| US-20230390406-A1 | Star Polymer Drug Conjugates | CCND3, CCND2, DRD3 | PDPK1 4103/4885GDA 3610/4885PI4KA 1072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.